+ Watch INFI
on My Watchlist
The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions.
Sometimes I like to play a mental exercise with biotech stocks. I call it Then and Now. I look at the stock now and a few months ago and try and figure out what justified a massive change in the share price. Let's play Then and Now with Infinity.Then (March 16, 2011): Share price 5.33. Cash 101M. Controlled phase II trials of oral Hedgehog inhibitor IPI-926 in advanced chondrosarcoma and in metastatic pancreatic cancer have recently been initiated. IPI-926 is partnered with Purdue/Mundipharma with a funding commitment of 85M in 2011 and 110M in 2012. Phase II studies of oral FAAH inhibitor IPI-940 for pain as well as initial clinical trials of oral p3kinase inhibitor IPI-145 are planned for later this year. Phase I data for Hsp90 inbhibitor retaspimycin with docetaxel in solid tumors will also be released later this year. Now (July 18, 2011): Share price 9.0. Cash 91M. Enrollment in phase II trial of IPI-926 and gemcitabine in pancreatic cancer is expected to be complete by the end of 2011. A phase I trial of IPI-926 and Erbitux in advanced head and neck cancer has been initiated at the University of Colorado as part of an investigator-sponsored trial program. The phase II trial of IPI-926 in advanced chondrosarcoma continues to enroll, and a phase II trial of IPI-926 in myelofibrosis will be initiated later this quarter. In 5/11 company initiated a phase II trial of retaspimycin with docetaxel in lung cancer.As far as I can tell there isn't much in the way of elapsed or upcoming catalysts to explain a 70% increase in share price from recent lows over the last four months. There hasn't even been a coordinated pumping effort on Seeking Alpha. So what accounts for it? Stochastic price movement? Irrational speculation? Low float manipulation? Or a combination of the above? In the spirit of Taco Bell, I'll call it stochirrapulation. Infinity hasn't won my confidence with a series of failures in their Hsp90 inhibitor program and I don't have any strong reason to have faith in their Hedgehog inhibitor program. I'm betting this move is pure stochirrapulation.
Your ideas and your comments are much appreciated.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions